Research map: Rethinking Immunotherapy Drug Development in Head and Neck Squamous Cell Carcinoma: The Role of Biologic Context and Treatment Sequencing

Back to the article

Papers in this map

  1. Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer · Martin Reck · 2016 · 10309 citations · Cited by this paper
  2. The Male Predominance in HBV-Related Hepatocellular Carcinoma: Unraveling the Axis of Androgen Receptor, Viral Replication, and Immune Evasion via NKG2D Ligands · 2026 · Related
  3. Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer · H. Borghaei · 2015 · 9564 citations · Cited by this paper
  4. Hub Gene Clusters Reveal Dysregulated Synaptic Neurotransmitter Signaling Pathways and Drug Repurposing Prospect in Brain Tumors · 2026 · Related
  5. Pembrolizumab plus Chemotherapy in Metastatic Non–Small-Cell Lung Cancer · Leena Gandhi · 2018 · 6765 citations · Cited by this paper
  6. Navigating Rarity: Pathological Challenges and Diagnostic Ambiguity in Rare Gliomas—A Case Series with a Focus on Personalized Treatment and Quality of Life · 2025 · Related
  7. Pembrolizumab versus Ipilimumab in Advanced Melanoma · Caroline Robert · 2015 · 5982 citations · Cited by this paper
  8. Molecular Insight and Antioxidative Therapeutic Potentials of Plant-Derived Compounds in Breast Cancer Treatment · 2025 · Related
  9. Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck · Robert Louis Ferris · 2016 · 5197 citations · Cited by this paper
  10. Advancing Immunotherapy in Cervical Cancer: Biological Rationale, Clinical Evidence, and Biomarker Standardization · 2026 · Related
  11. Platinum-Based Chemotherapy plus Cetuximab in Head and Neck Cancer · Jan B. Vermorken · 2008 · 3767 citations · Cited by this paper
  12. Cancer Therapy-Related Cutaneous Toxicities: Prognostic Biomarkers, Immunologic Endotypes, and Novel Therapeutic Strategies · 2026 · Related
  13. Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study · Barbara Ann Burtness · 2019 · 3349 citations · Cited by this paper
  14. Transformation of NSCLC to SCLC: Insights into Molecular Alterations, Tumor Origin, and Therapeutic Advancements · 2026 · Related
  15. Epidemiology, Risk Factors, and Prevention of Head and Neck Squamous Cell Carcinoma · Adam A. Barsouk · 2023 · 746 citations · Cited by this paper
  16. Obesity as a Whole-Body Regulatory Disorder: A Systems Biology Framework for Metaflammation, Accelerated Aging, and Colorectal Cancer Risk · 2026 · Related
  17. Immunology and Immunotherapy of Head and Neck Cancer · Robert Louis Ferris · 2015 · 682 citations · Cited by this paper
  18. Melanotransferrin as a Potential Target for the Selective Killing of Melanoma and Triple-Negative Breast Cancer Cells In Vitro Using Novel SNAP-Tag-Based Antibody–AURIF Conjugate · 2025 · Related
  19. Pembrolizumab With or Without Chemotherapy in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: Updated Results of the Phase III KEYNOTE-048 Study · Kevin Joseph Harrington · 2022 · 524 citations · Cited by this paper
  20. Precision Medicine for Older AML Patients · 2025 · Related
  21. Neoadjuvant and Adjuvant Pembrolizumab in Locally Advanced Head and Neck Cancer · Ravindra Uppaluri · 2025 · 389 citations · Cited by this paper
  22. Durvalumab with or without tremelimumab in patients with recurrent or metastatic head and neck squamous cell carcinoma: EAGLE, a randomized, open-label phase III study · Robert Louis Ferris · 2020 · 381 citations · Cited by this paper
  23. Safety and Efficacy of Durvalumab With or Without Tremelimumab in Patients With PD-L1–Low/Negative Recurrent or Metastatic HNSCC · Lillian L. Siu · 2018 · 316 citations · Cited by this paper
  24. Human Papillomavirus and Rising Oropharyngeal Cancer Incidence in the United States · Anil K. Chaturvedi · 2023 · 298 citations · Cited by this paper
  25. Pembrolizumab plus cetuximab in patients with recurrent or metastatic head and neck squamous cell carcinoma: an open-label, multi-arm, non-randomised, multicentre, phase 2 trial · Assuntina Gesualda Sacco · 2021 · 269 citations · Cited by this paper
  26. Pembrolizumab versus cetuximab concurrent with radiotherapy in patients with locally advanced squamous cell carcinoma of head and neck unfit for cisplatin (GORTEC 2015-01 PembroRad): a multicenter, randomized, phase II trial · Yungan Tao · 2022 · 192 citations · Cited by this paper
  27. Nivolumab Plus Ipilimumab Versus EXTREME Regimen as First-Line Treatment for Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck: The Final Results of CheckMate 651 · Robert I. Haddad · 2022 · 171 citations · Cited by this paper
  28. Antitumor immune responses induced by ionizing irradiation and further immune stimulation · Benjamin Frey · 2013 · 143 citations · Cited by this paper
  29. Radio-Immunotherapy-Induced Immunogenic Cancer Cells as Basis for Induction of Systemic Anti-Tumor Immune Responses – Pre-Clinical Evidence and Ongoing Clinical Applications · Anja Derer · 2015 · 110 citations · Cited by this paper
  30. Mechanisms of tumor resistance to immune checkpoint blockade and combination strategies to overcome resistance · Xiaoting Zhou · 2022 · 109 citations · Cited by this paper
  31. JAVELIN Head and Neck 100: A Phase III Trial of Avelumab and Chemoradiation for Locally Advanced Head and Neck Cancer · Yao Yu · 2018 · 82 citations · Cited by this paper
  32. Efficacy and Safety of Nivolumab Plus Ipilimumab vs Nivolumab Alone for Treatment of Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck · Kevin Joseph Harrington · 2023 · 79 citations · Cited by this paper
  33. Concurrent Cetuximab and Nivolumab as a Second-Line or beyond Treatment of Patients with Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma: Results of Phase I/II Study · Christine H. Chung · 2021 · 60 citations · Cited by this paper
  34. Global burden of head and neck cancer: Epidemiological transitions, inequities, and projections to 2050 · Haowei Sun · 2025 · 59 citations · Cited by this paper
  35. Atezolizumab in High-Risk Locally Advanced Squamous Cell Carcinoma of the Head and Neck · Robert I. Haddad · 2025 · 54 citations · Cited by this paper
  36. Nivolumab added to cisplatin and radiotherapy versus cisplatin and radiotherapy alone after surgery for people with squamous cell carcinoma of the head and neck at a high risk of relapse (GORTEC 2018-01 NIVOPOST-OP): a randomised, open-label, phase 3 trial · Jean Bourhis · 2025 · 50 citations · Cited by this paper
  37. Multi-omics in immunotherapy research for HNSCC: present situation and future perspectives · Xuan-Hao Liu · 2025 · 32 citations · Cited by this paper
  38. Pembrolizumab plus epacadostat in patients with recurrent/metastatic head and neck squamous cell carcinoma (KEYNOTE-669/ECHO-304): a phase 3, randomized, open-label study · Byoung Chul Cho · 2024 · 18 citations · Cited by this paper
  39. Treatment decision-making factors and sequencing in recurrent and/or metastatic squamous cell carcinoma of the head and neck · Petr Szturz · 2025 · 13 citations · Cited by this paper

Source: OpenAlex (CC0)